Adamed Pharma’s ESG Report

Adamed Pharma has published its ESG report for 2021-2022. The report presents both data and a number of best practice examples highlighting Adamed Pharma’s commitment to sustainability.

The ESG report covers the period from 1 January 2021 to 31 December 2022. Adamed Pharma is a company that is aware of its social, environmental and economic impact. We follow ethical and legal standards in every aspect. Not only are we committed to top standards, but we also set them. One of Adamed Pharma’s core values guiding our activities is broadly defined responsibility.

“Sustainability and social responsibility are the foundations of all activities carried out under the Adamed brand. We are happy to release the latest edition of the ESG report for 2021-2022, and we are convinced that the information we provide will help you better understand the character and impact of our organisation on patient health, the healthcare system or the business environment. All activities – both in terms of improving drug security, innovation and social responsibility – would not have been possible without the day-to-day work of all Adamed associates in the Polish and foreign markets,” says Katarzyna Dubno, Director for External Relations, ESG and Health Economics.

Adamed Pharma’s primary goals, which are further described in the report, include:

• supporting the public in caring for health – ensuring drug security and seeking innovative therapies;
• caring for associates by strengthening their competencies and offering attractive career paths within the organisation;
• caring for the environment – both the natural environment and relationships with local communities;
• supporting talented youth and promoting exact sciences.

The 2021-2022 ESG report presents Adamed Pharma’s activities including:

• Ethical operations – adhering to the highest ethical standards in the manufacture and sale of medicines;
• Responsible manufacturer – manufacturing top quality medicinal products, of which some address chronic diseases of civilisation. Adamed’s business is founded on deep understanding of patients, their needs and expectations;
• Environmental and climate protection – reducing the consumption of raw materials and energy, smart circular economy, recycling of marketed packaging, and measuring carbon footprint are the main areas of activity in the “E” area;
• R&D activities – the company’s main ambition is to find new, effective and safe therapies for patients all over the world and to foster knowledge-based innovation. Innovation at Adamed is not only the search for original drugs, but also a process that involves improving existing products;
• Responsible employer – Adamed’s success is based on the knowledge, experience and commitment of all associates. Adamed Pharma supports professional ambitions and enables systematic development of competencies of its associates;
• Responsible partner – responsibility is one of Adamed’s core values, which guides the company in all its operations. Adamed ensures drug security to Poles and supports the public in taking care of their health through programmes such as Adamed for the Family, Adamed for Seniors and Adamed Expert. The company supports the development of talented youth and promotes exact and natural sciences through the ADAMED SmartUP programme. Despite its global operations, Adamed Pharma pays taxes in Poland, supporting the country’s economy. The company invests its profits to accelerate innovation in Poland – since 2001, we have spent PLN 2.1 billion on investment projects and R&D, and as much as PLN 168 million in 2022 alone.

Take a look at Adamed Pharma’s latest ESG report which is available at www.adamed.com.